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Background: Intratumoural heterogeneity (ITH) is well recognised in prostate cancer (PC), but its role in high-risk disease is
uncertain. A prospective, single-arm, translational study using targeted multiregion prostate biopsies was carried out to study
genomic and T-cell ITH in clinically high-risk PC aiming to identify drivers and potential therapeutic strategies.
Patients and methods: Forty-nine men with elevated prostate-specific antigen and multiparametric-magnetic resonance
imaging detected PC underwent image-guided multiregion transperineal biopsy. Seventy-nine tumour regions from 25
patients with PC underwent sequencing, analysis of mutations, copy number and neoepitopes combined with tumour
infiltrating T-cell subset quantification.
Results: We demonstrated extensive somatic nucleotide variation and somatic copy number alteration heterogeneity in high-
risk PC. Overall, the mutational burden was low (0.93/Megabase), but two patients had hypermutation, with loss of mismatch
repair (MMR) proteins, MSH2 and MSH6. Somatic copy number alteration burden was higher in patients with metastatic
hormone-naive PC (mHNPC) than in those with high-risk localised PC (hrlPC), independent of Gleason grade. Mutations were
rarely ubiquitous and mutational frequencies were similar for mHNPC and hrlPC patients. Enrichment of focal 3q26.2 and
3q21.3, regions containing putative metastasis drivers, was seen in mHNPC patients. We found evidence of parallel evolution
with three separate clones containing activating mutations of b-catenin in a single patient. We demonstrated extensive
intratumoural and intertumoural T-cell heterogeneity and high inflammatory infiltrate in the MMR-deficient (MMRD) patients
VC The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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and the patient with parallel evolution of b-catenin. Analysis of all patients with activating Wnt/b-catenin mutations
demonstrated a low CD8þ/FOXP3þ ratio, a potential surrogate marker of immune evasion.
Conclusions: The PROGENY (PROstate cancer GENomic heterogeneitY) study provides a diagnostic platform suitable for
studying tumour ITH. Genetic aberrations in clinically high-risk PC are associated with altered patterns of immune infiltrate in
tumours. Activating mutations of Wnt/b-catenin signalling pathway or MMRD could be considered as potential biomarkers for
immunomodulation therapies.
Clinical Trials.gov Identifier: NCT02022371
Key words: prostate cancer, intratumoural heterogeneity, neoepitopes, tumour inﬁltrating lymphocytes, wnt signalling,
mismatch repair
Introduction
Prostate cancer (PC) is the second most common malignancy in
men with an incidence of 1.1 million men per year leading to an
estimated 307,000 deaths worldwide [1]. While the prognosis of
clinically low-risk PC is excellent [2], there is significant mortality
associated with clinically high-risk disease, with approximately
20%–25% 10-year cancer-specific mortality despite radical treat-
ments [3].
A key challenge in PC is to identify patients with potentially le-
thal disease while avoiding the morbidity of overtreatment in pa-
tients with indolent disease. Accurate risk stratification has been
confounded by underestimation of disease burden using stand-
ard transrectal ultrasound-guided biopsies and extensive tumour
heterogeneity of primary PC [4–6]. A recent improvement on
transrectal ultrasound-guided biopsies is targeted magnetic res-
onance imaging (MRI)-guided biopsies that increase the likeli-
hood of sampling clinically significant disease [7].
Multi-regional sampling of tumours allows measurement of
intratumoural heterogeneity, a prognostic entity in PC [8]. To
date, in-depth exploration of genomic ITH with multiregion
sequencing (M-Seq) in the primary PC has relied on prostatectomy
patient series [9, 10] to provide good-quality tissue; however, this
has enriched for clinically low- and intermediate-risk disease [5, 6].
Tumour infiltrating lymphocyte density has been shown, albeit
inconsistently, to be prognostic in PC [11–13]. The impact of tu-
mour genetics on prostate immunobiology is unclear and de-
ciphering this could improve risk stratification, prognostication
and immunotherapeutic approaches.
We conducted the PROGENY study (PROstate cancer
GENomic heterogeneitY) to attain high-quality multi-regional
prostate biopsies to determine the driver and evolutionary events
of clinically high-risk PC at the time of diagnosis and to correlate
genomic and immune parameters.
Methods and materials
Patient selection
Between September 2013 and December 2015, 49men with a prostate-spe-
cific antigen15, a multi-parametric MRI detectable lesion in the prostate
and no prior prostate-directed biopsies or treatments were enrolled into
the PROGENY study, with local ethics committee approval. Of these, 23
patients and a further 2 contemporaneous patients from the institutional
biobank met the criteria for the planned genetic and T-cell analysis (sup-
plementary Table S1 and Figure S1, available atAnnals of Oncology online).
Tissue procurement
Multi-regional PC biopsies were obtained using multi-parametric MRI,
image-fusion transperineal template targeting as described previously [7]
(supplementary Figure S2, available at Annals of Oncology online). Blood
samples were obtained before the biopsy for isolation of germline DNA.
Sequencing studies
Tumour DNAwas extracted using the AllprepMicro Kit (Qiagen, CA) and
germline DNA extracted with the DNeasy Blood & Tissue Kit (Qiagen,
MD) following the manufacturer’s instructions. Further details are con-
tained in the supplementary data, available atAnnals of Oncology online.
Immunohistochemistry
Single and multiplexed IHC was carried out as described previously [14].
Antibody details are in supplementary Table S2, available at Annals of
Oncology online. TM andML jointly carried out quantification of inflam-
matory infiltrate (INIF), blinded to patient characteristics. Samples with
8% (median of all samples) INIF (15/25 patients) in any one region
were subjected to digital image analysis. These correlated well with the
manual estimation (R2¼ 0.71) (supplementary Figures S3 and S4, avail-
able at Annals of Oncology online).
Results
The extent of intratumoural heterogeneity in
high-risk PC
Across 25 prospectively recruited patients, M-Seq from 79 tu-
mour regions identified a total of 4484 exonic somatic nucleotide
variations (SNV) (3382 non-silent), of which 1962 were ubiqui-
tous, 495 were shared and 2027 were private (Figure 1A). The
overall estimation of exonic SNV burden was 0.93 mutations per
megabase (median, range, 0.18–33 per megabase), consistent
with prior studies in PC [15].
The overall fraction of the genome subject to somatic copy
number alterations (SCNAs) was 23.1% (median, range 1.9%–
41.6%). Of this fraction, a median of 52.3% (range 2.1%–95.3%)
was heterogeneous (Figure 1A). The degree of SNV and SCNA
heterogeneity among the tumours was positively correlated
(Figure 1B) (r¼ 0.49, P¼ 0.013, Pearson’s).
Two patients, BP0001 and PR0103, had markedly elevated
SNV rates. BP0001 had a previous diagnosis of Lynch Syndrome
and was found to harbour a germline mutation in MSH6
(p.G39E, rs1042821) and a somatic heterozygous deletion en-
compassing the region encoding for MSH2 and MSH6, resulting
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in a hemizygous variant in MSH6. PR0103 had a somatic 10Mb
deletion overlapping MSH2 and MSH6 and a 5 kb somatic dele-
tion across MSH2, leading to biallelic loss of MSH2. IHC of
MSH2 and MSH6 in both of these patients showed complete loss
of protein expression in the tumours (supplementary Figures S5
and S6, available at Annals of Oncology online).
Genomic events enriched in patients presenting
with metastatic disease
After the diagnostic biopsy, 12/25 patients were found to have
metastatic disease on imaging (mHNPC) and 13 patients had
localised PC with high risk for metastatic disease (hrlPC).
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Figure 1. Intratumoural heterogeneity in prostate cancer at the somatic nucleotide variation (SNV) and somatic copy number alteration
(SCNA) levels. (A) Number of somatic exonic mutations identiﬁed in each tumour region, fraction of SNVs and SCNAs that were ubiquitous
(present in every tumour region of a given patient) (blue), shared (present in more than one tumour region, but not all) (light orange) or pri-
vate (present in only one tumour region) (dark orange). Data tracks below indicate if patient was metastatic on presentation (red), Gleason
grade (shades of green), level of tumoural inﬂammatory inﬁltrate (shades of brown), and if the tumour had undergone whole-genome dou-
bling (purple, triangle indicating heterogeneous genome doubling). (B) Scatterplot showing correlation between degree of SNV and SCNA
heterogeneity. (C and D) Boxplots comparing the fraction of genome affected by SCNA and SNV mutational burden in metastatic hormone
naive prostate cancer (mHNPC) versus high-risk localised prostate cancer (hrlPC).
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mHNPC primary tumours had significantly higher burden
of SCNAs compared with hrlPC tumours (29.6%6 10.6% ver-
sus 12.5%6 8.9%, P¼ 7.57  104, Mann–Whitney U test)
(Figure 1C) and this was independent of Gleason grade.
Comparing mHNPC and hrlPC patients, there was no significant
difference in the proportion of heterogeneous SCNAs (P¼ 0.89,
Mann–Whitney U test), overall mutational burden (P¼ 0.74,
Mann–Whitney U test ) (Figure 1D), or proportion of heteroge-
neous mutations (P¼ 0.11, Mann–WhitneyU test).
To explore the relative frequency of SNVs and SCNAs in
mHNPC and hrlPC, we focused on driver genes identified in
previous PC series (Figure 2) [16, 17]. We found no significant
differences between mHNPC and hrlPC tumours. However,
there was a significant enrichment of 3q26.2 and 3q21.3 gains in
mHNPC compared to hrlPC tumours (5/12 versus 1/13 and 3/12
versus 1/13, respectively) (Figure 3), which remained signifi-
cantly enriched after controlling for the differing levels of SCNAs.
Parallel evolution of wnt/b-catenin pathway
We observed one tumour (PR0139) with three distinct CTNNB1
mutations, all previously described gain-of-function mutations
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in exon 3 ofCTNNB1 leading to stabilisation of b-catenin and ac-
tivation of Wnt/b-catenin signalling (Figure 4A). Phylogenetic
analysis of the clonal structure in this tumour revealed that all 3
CTNNB1 mutations were in three separate subclones (Figure
4B), providing strong evidence for parallel evolution leading to
activation of theWnt/b-catenin pathway in this tumour.
Temporal order of driver events in clinically
high-risk PC
To explore the relative timing of driver events in PC, we utilised a
modified version of Pyclone to cluster the mutations (supplemen-
tary Methods, available at Annals of Oncology online ). Consistent
with previous reports about PC tumourigenesis [18, 19], we
observed ETS fusions and mutations or loss of TP53 to be early
(clonal) events (Figure 2 and supplementary Table S3, available at
Annals of Oncology online), PTEN a later event (60% clonal), and
mutations or deletions of chromatin modifiers (KMT2C, KMT2D
and CHD1) as a later (subclonal) event (Figure 2).
The landscape of SCNAs was also highly consistent with previ-
ous studies [15, 17], (Figure 3). In general, we observed that the
majority of recurrent SCNA peaks were early events across most
tumours in the cohort, aside from 8q and 7p gains, which
occurred heterogeneously in 7/13 and 4/6 tumours.
Next, we investigated the mutational processes in the two pa-
tients with defective MMR (supplementary Figure S7, available at
Annals of Oncology online). BP0001, who had germlineMSH2 and
MSH6 aberrations, had a high proportion of ubiquitousmutations
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associated with Signature 6 (DNA repair) compared with PR0103
(41.3% versus 8.6%) in keeping with loss of MMR as an early
tumourigenic process. Conversely, ubiquitous mutations in
PR0103 were mainly associated with Signature 1 (age), suggesting
thatMMRDwas not an initial driver of this tumour, but rather the
acquired biallelic loss ofMSH2was a later event that provided a se-
lective advantage, possibly through an acceleratedmutation rate.
T-cell infiltrate heterogeneity and neoantigen burden
There was considerable variation in the total inflammatory infil-
trate (INIF) (CD8þ or CD4þ and/or FoxP3þ cells in tumour re-
gion) between patients (Figure 5A), as well as between different
regions within each patient. This intratumoural heterogeneity of
INIF is well illustrated by PR0123, where 4 separate core biopsies
have different levels of INIF (mean 15%, range 5%–25%) (Figure
5B).
We noted that both PR0103 and BP0001 had extensive INIF
(maximal infiltrate >20% of all nucleated cells per biopsy) (2/2)
compared with patients without MMR deficiency, where only
6/23 had extensive INIF. Patients PR0112 and PR0129 had
ubiquitous and heterozygous loss of MLH1 and MSH2 respect-
ively, but this was not associated with high mutational burden
or high INIF. As mutational load has been reported to correlate
with neoantigen load and neoantigens can elicit a clonal expan-
sion of neoantigen reactive T- (NART) cells [20–22], we
hypothesised that the abundant INIF in these MMRD
deficient tumours might be related to a high neoantigenic
burden. Consistent with this, PR0103 and BP0001 displayed a
high neoantigen burden. However, extending this analysis to all
25 patients in this cohort, there was no association between
neoantigen burden nor clonal neoantigen burden and INIF
(supplementary Figure S8, available at Annals of Oncology
online).
Wnt signalling and modulation of immune response
Activation of tumour intrinsic Wnt/b-catenin signalling in mel-
anoma has recently been reported to lead to T-cell exclusion from
the tumour preventing anti-tumour immunity [23]. However,
PR0139 who had parallel evolution of activated b-catenin, had
high levels of CD8þ infiltrate (Figure 5A), but was noted to also
have high FOXP3þ levels giving a low CD8þ/FOXP3þ ratio.
A low ratio of tumour-infiltrating CD8þ and FOXP3þ lymphocytes
is increasingly being recognised as a measure of immune suppres-
sion and as a potential prognostic indicator [24–26].
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In our cohort, the 15 patients with levels of INIF at or above the
median underwent digital pathology analysis. Of these patients, 7/
15 had activatingmutations in theWnt pathway (gain-of-function
CTNNB1 mutations, RSPO2 amplification, and deletion of APC,
RNF43 and ZNRF3 [17, 27]). We observed a significantly lower
CD8þ/FOXP3þ ratio in patients with tumours containing activat-
ing mutations of the Wnt pathway compared with wild-type tu-
mours (2.656 1.2 versus 6.086 5.0, P¼ 0.043, Mann–WhitneyU
test) (Figure 5C).
Discussion
We have conducted the largest prospective clinical cohort study
of M-Seq in high-risk PC patients and carried out an integrated
genomic and tumour immune infiltrate analysis. Uniquely, we
have compared M-Seq of diagnostic prostate biopsies from
mHNPC and hrlPC and demonstrated increased SCNA in
mHNPC patients, consistent with previous reports correlating
biochemical recurrence following prostatectomy with high
SCNA in localised disease [28]. We observed no differences in
SNV frequency between mHNPC and hrlPC patients, which is
surprising given the large differences seen in other studies be-
tween localised PC and pre-treated metastatic castrate-resistant
prostate cancer [17, 29]. This may be a consequence of the small
sample size or may suggest that unlike SCNA changes, SNV accu-
mulation is a later evolutionary event, possibly as a result of the
selective pressure of treatment. In this study, there was enrich-
ment for gains of 3q26.2 and 3q21.3 in mHNPC patients. Both
amplicons contain genes previously implicated in PC, e.g. 3q26.2
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inﬁltrate. (B) Multiplex immunohistochemistry (IHC) analysis of four different prostate core biopsies (R1–4) from a patient, PR0123, showing
heterogeneity in T-cell inﬁltration. CD8 staining in red, CD4 in brown and FoxP3 in blue. (C) Boxplot comparing CD8þ/FOXP3þ ratios be-
tween tumours with and without somatic activation of Wnt pathway (gain-of-function mutation in CTNNB1, ampliﬁcation in RSPO2, loss in
APC, RNF43 and ZNRF3) across 15 tumours with digital image analysis.
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contains PRKCI, expression of which is associated with biochem-
ical relapse following prostatectomy [30]. Interestingly, these
gains in copy number are early evolutionary events, and the fact
that these focal gains are enriched in patients presenting with
metastatic disease suggests that some PCs are hard-wired to be
aggressive.
We describe the first report of parallel evolution of Wnt
signalling in PC, where 3 separate gain-of-function mutations of
b-catenin (CTNNB1) were identified in a single tumour. This is
similar to the distinctTMPRSS-ERG fusions identified in several re-
gions of the primary prostate tumour [5] and alterations of SETD2,
PTEN and KDM5C in renal cancer [31]. Parallel evolution of the
Wnt pathway, a pathway already implicated in PC cell growth, pro-
liferation and epidermal to mesenchymal transition [32], points to
its biological importance in PC. Unlike mouse melanoma models,
where tumour intrinsic Wnt/b-catenin signalling led to T-cell ex-
clusion from the tumour [23], we observed that patients with acti-
vated Wnt/b-catenin signalling can have normal or high levels of
INIF, but that this is predominantly CD8þ/FOXP3þ low, consistent
with a dysfunctional T-cell response. Future studies will be needed
to further elucidate the role and mechanism of Wnt/b-catenin sig-
nalling in immunemodulation in human PC, which is of particular
interest given the number of potential novel drugs targeting this
pathway.
We identified two patients with hypermutation associated with
MMR deficiency and high INIF, the latter being similar to a re-
port of 12/16 (75%) men at risk of Lynch syndrome and diag-
nosed with PC having significant INIF [33]. Similar to reports in
advanced PC [34], our hrlPC patients with MMRD had complex
structural rearrangements of DNA repair genesMSH2 andMSH6
leading to inactivation. Overall however, we did not demonstrate
an association with INIF and neoepitope burden, but given the
small number of patients with DNA repair aberrations in this ser-
ies, this analysis is underpowered. MMRD deficiency has been
associated with response to immune checkpoint inhibition in a
number of tumour types including PC [35, 36]. The finding of
high INIF and neoepitope burden in some PC patients in this
study supports current attempts to evaluate the role of muta-
tional burden and neoepitopes in prospective therapeutic clinical
trials (NCT02113657 and NCT03061539).
We have demonstrated extensive intratumoural heterogeneity of
INIF in primary PC. The impact of this on prognosis and predicting
treatment response is unknown, but future studies testing INIF as a
potential biomarker will need to consider testing multiple tumour
regions or developing a liquid biopsy strategy.
In conclusion, our findings reveal how mutational and SCNA
changes may drive aggressive metastatic PC. We show that acti-
vatedWnt signalling is correlatedwith immune suppression in pri-
mary PC, and suggest that activated Wnt/b-catenin, MMR, high
INIF and the CD8þ/FOXP3þ ratio should be explored as predict-
ive biomarkers for immunotherapeutics in prostate cancer.
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